Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › spironolactone

spironolactone

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of spironolactone

29 trials tracked of spironolactone: 12 in phase 3 or 4 and 6 with published results. The most-cited published study has 77 citations.

29Trials tracked
12Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 6 Phase 3 6 Phase 2 13 Phase 1 1 Other / NA 3
  1. Phase 4 Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy Completed · 77 cited
  2. Phase 3 Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy Completed · 64 cited
  3. Phase 3 Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Completed · 28 cited
  4. Phase 4 Antiarrhythmic Effects of Spironolactone in Patients With ICDs Completed · 19 cited
  5. Phase 4 Effect of Aldosterone on Energy Starvation in Heart Failure Completed · 19 cited
  6. Phase 4 Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Trial Completed · 15 cited
Show 23 more trials
  1. Phase 4 Spironolactone After Liver Transplant Completed
  2. Phase 4 Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone Completed
  3. Phase 3 Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function Completed
  4. Phase 3 The Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant Hypertension Completed
  5. Phase 3 Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF) Completed
  6. Phase 3 PIE II: Pharmacological Intervention in the Elderly II Completed
  7. Phase 2 Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men Completed
  8. Phase 2 Transgender Estradiol Affirming Therapy Completed
  9. Phase 2 A Study of LY2623091 in Participants With High Blood Pressure Completed
  10. Phase 2 Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure Completed
  11. Phase 2 Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease Completed
  12. Phase 2 Tissue Sodium in Pre-hypertensive Patients Completed
  13. Phase 2 Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease Completed
  14. Phase 2 Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab Completed
  15. Phase 2 The Effect in Renal Function on Patients With Type 1 Cardiorenal Syndrome Treated With Two Strategies of Furosemide. Completed
  16. Phase 2 Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease Completed
  17. Phase 2 Biomarker Guided Therapies in Stage A/B Heart Failure Completed
  18. Phase 2 Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial Completed
  19. Phase 2 Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN) Completed
  20. Phase 1 Evaluation of CLP With and Without Spironolactone in Heart Failure Patients With Chronic Kidney Disease Completed
  21. N/A Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease Completed
  22. N/A Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications Completed
  23. N/A Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment Completed

Showing the 29 most-cited and recently-updated of 29 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Systematic review and meta-analysis of MRAs in dialysis patients shows reduced nonfatal CVD events but elevated hyperkalemia and gynecomastia risks
Nephrology Meta-analysis
Systematic review and meta-analysis of MRAs in dialysis patients shows reduced nonfatal CVD events but elevated hyperkalemia and gynecomastia risks New analysis shows dialysis drugs cut heart attacks but raise dangerous potassium risks
This systematic review and meta-analysis evaluated mineralocorticoid receptor antagonists (MRAs) in adults on maintenance dialysis.
A large review of dialysis patients found that specific heart drugs reduced nonfatal heart events but increased risks of severe potassium bu…
Apr 30, 2026
LP-184 Alone and With Spironolactone in Recurrent Glioblastoma: Phase 1a Results
Oncology Phase I
LP-184 Alone and With Spironolactone in Recurrent Glioblastoma: Phase 1a Results New drug combo may help brain cancer patients who have run out of options
This Phase 1a trial in 63 patients (16 with glioblastoma) found LP-184 was well tolerated but with more transaminitis and thrombocytopenia i…
A new drug combination could help brain cancer patients by making their current medicine work much harder inside the tumor.
medRxiv Apr 25, 2026
Spironolactone reduces cardiovascular events in HFpEF patients with increased LV mass or left atrial volume
Cardiology RCT
Spironolactone reduces cardiovascular events in HFpEF patients with increased LV mass or left atrial volume Spironolactone Saves Lives in Specific Heart Failure Types
This post hoc analysis of the TOPCAT randomized controlled trial evaluated spironolactone in 757 participants with heart failure with preser…
Spironolactone cuts death risk for heart failure patients with enlarged heart chambers, proving that heart size matters just as much as pump…
Apr 12, 2026